Earth Science Tech, Inc. (ETST) Accelerates the Development and Commercialization of Products
- Company announces its membership in Défi Montréal, Canada’s largest business acceleration program
- Partnership with Laboratories BNK Canada, Inc. allows ETST to commercialize its new testing services more quickly
- Strategic acquisition aimed at improving access to funding for development of treatments for various diseases
Earth Science Tech, Inc. (OTC: ETST), a Florida-based biotechnology company that operates in the fields of hemp cannabinoids, nutraceuticals, pharmaceuticals and medical devices, is taking active measures to accelerate its development and growth. On March 22, 2018, ETST announced its membership in the 16th cohort of Défi Montréal, the largest innovative business acceleration program in Quebec. Martin Duchaîne, founder of Défi Montréal, has advised or assisted over 900 entrepreneurs in his 20-year career. This new membership is expected to accelerate the development and commercialization of new ETST products in Canada and overseas (http://nnw.fm/2uUtV).
Through ETST’s connection with Défi Montréal, key individuals have already been brought on board to advance the acceleration of operations. In January 2018, ETST announced a deal with Laboratories BNK Canada, Inc. for clinical studies related to the MSN-2 medical device. The MSN-2 is a home kit designed for the detection of sexually transmitted infections (STIs) from a self-obtained gynecological specimen. MSN-2 has been confirmed through studies to detect chlamydia. The company is working to validate similar results for gonorrhea. Testing for trichomoniasis, as well as different serotypes of the human papillomavirus (HPV), are expected to be added in the near future. Partnering with Laboratories BNK offers ETST an accelerated plan of development for more products while cutting costs and, ideally, treating more patients. This arrangement gives ETST the means to accelerate the commercialization of its new testing services while it works toward its ultimate goal of halting the spread of STIs.
ETST holds three wholly owned subsidiaries, including Earth Science Pharmaceutical Inc., Cannabis Therapeutics Inc. and KannaBidioid Inc. In 2017, ETST acquired Canna Inno Laboratories Inc. as a strategic move that gave ETST access to government grants. The first of these grants was awarded from the Government of Québec for innovation in the pharmaceutical industry and will support the pre-launch process of ETST’s three CBD-based products that aim to prevent common causes of cancer and help reduce occurrence rates.
ETST strives to discover solutions for conditions with no current effective treatment, targeting diseases for which the benefits of CBD have been demonstrated by researchers worldwide. The move to accelerate the development and commercialization of these products is an effort to improve treatments for different diseases on a global scale.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Company announces its membership in Défi Montréal, Canada’s largest business acceleration program
- Partnership with Laboratories BNK Canada, Inc. allows ETST to commercialize its new testing services more quickly
- Strategic acquisition aimed at improving access to funding for development of treatments for various diseases
Earth Science Tech, Inc. (OTC: ETST), a Florida-based biotechnology company that operates in the fields of hemp cannabinoids, nutraceuticals, pharmaceuticals and medical devices, is taking active measures to accelerate its development and growth. On March 22, 2018, ETST announced its membership in the 16th cohort of Défi Montréal, the largest innovative business acceleration program in Quebec. Martin Duchaîne, founder of Défi Montréal, has advised or assisted over 900 entrepreneurs in his 20-year career. This new membership is expected to accelerate the development and commercialization of new ETST products in Canada and overseas (http://nnw.fm/2uUtV).
Through ETST’s connection with Défi Montréal, key individuals have already been brought on board to advance the acceleration of operations. In January 2018, ETST announced a deal with Laboratories BNK Canada, Inc. for clinical studies related to the MSN-2 medical device. The MSN-2 is a home kit designed for the detection of sexually transmitted infections (STIs) from a self-obtained gynecological specimen. MSN-2 has been confirmed through studies to detect chlamydia. The company is working to validate similar results for gonorrhea. Testing for trichomoniasis, as well as different serotypes of the human papillomavirus (HPV), are expected to be added in the near future. Partnering with Laboratories BNK offers ETST an accelerated plan of development for more products while cutting costs and, ideally, treating more patients. This arrangement gives ETST the means to accelerate the commercialization of its new testing services while it works toward its ultimate goal of halting the spread of STIs.
ETST holds three wholly owned subsidiaries, including Earth Science Pharmaceutical Inc., Cannabis Therapeutics Inc. and KannaBidioid Inc. In 2017, ETST acquired Canna Inno Laboratories Inc. as a strategic move that gave ETST access to government grants. The first of these grants was awarded from the Government of Québec for innovation in the pharmaceutical industry and will support the pre-launch process of ETST’s three CBD-based products that aim to prevent common causes of cancer and help reduce occurrence rates.
ETST strives to discover solutions for conditions with no current effective treatment, targeting diseases for which the benefits of CBD have been demonstrated by researchers worldwide. The move to accelerate the development and commercialization of these products is an effort to improve treatments for different diseases on a global scale.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
